It's Time! 3 Dodgy Pharma Stocks to Sell in February

Much like Big Tech companies ride the AI hype, pharma stocks are counting on valuation boosts from big drug hits and FDA approvals. This anticipation, however, brings to light the importance of discerning which pharma stocks to sell, as not all will sustain their high-growth promises, potentially generating double-digit profits in the short term.This perspective often invites speculation that leads to overvaluation. Over the last three months, the SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) is up nearly 22% ...